

M1.4

Diabetic Eye Disease: What's New?

10:45 Room 221

Latest Evidence Basis for Treatment of Diabetic Retinopathy and Diabetic Macular Edema*Brelen M**Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong*

The prevalence of diabetes continues to rise globally and it is now estimated that more than 4 million adults have diabetic retinopathy (DR). As ophthalmologists, we are becoming increasingly challenged in the screening and management of diabetic eye disease. Recently anti-Vascular Endothelial Growth Factors (anti-VEGFs) have revolutionised our management of patients with DR and diabetic macular edema (DME). However, there are still many challenges remained. We are still faced with the difficulty of early detection and prompt treatment of patients with potential sight-threatening retinopathy. The currently available treatments are both costly and have a heavy treatment burden on patients and caregivers. Finally, a substantial proportion of patients is failing treatments despite maximal medical therapy. There are therefore continuous improvements in the management of patients as well as novel therapies becoming available. This presentation will aim to summarise the most recent advances in these areas. The recent published and ongoing clinical trials in DR and DME management will be summarised. The learning objectives for audiences are to appreciate the challenges that still remain in the management of DR and DME and what new treatment options are now available.